The 2020 Innovation Contest held by Boehringer Ingelheim is the first biomedical innovation competition sponsored by multinational pharmaceutical company in China, aiming to develop collaborations and partnerships with Chinese innovative enterprises or individuals and stimulate local innovation. CommBio was successfully shortlisted for the final and won the most industry attention award. Dr. Xiang said after the competition: "It is an honor to participate in the BI Innovation Contest and receive the attention, which is an encouragement for CommBio to adhering to our mission of innovation. This also shows a new understanding of " innovation" in the Chinese drug development industry. We believe that "original and innovative drugs" will gradually become the mainstream of biomedical development in China."
The Director of the Shanghai Municipal People's Congress visited JLABS. CommBio research team introduced their research strategy. Director of the Shanghai Municipal People's Congress, showed strong interest in the intestinal biology field as well as the methodology of using bacteria as carries to deliver gene therapy and conducted a lively discussion.
The R&D team of CommBio led by Dr. Xiang was awarded the "Leading Talent in Science and Technology" Award by Suzhou Industrial Park. Suzhou Industrial Park, focusing on three key areas, industry, platform and policy, established an environment for high-end talent recruitment and cultivation. This environment serves as a fertile ground to flourish talents with innovative entrepreneurship. Talent acquisition and industrial upgrade are major features of the implementation of scientific and technological leading talent projects. Dr. Xiang, founder of CommBio, said that winning the leading talent award is not only the recognition for the scientific research team, but also a recognition for this novel field. We will adhere to our mission of innovation and develop transformative therapies for patients in China and around the world.
CommBio Therapeutics (Shanghai) Co., Ltd. is one of the pioneer biomedical companies focusing on intestinal biology and developing bacterial vector gene therapy in China. Since settled in Zhangjiang Pharma Valley Platform and Johnson & Johnson JLABS@Shanghai in 2019, CommBio has been advancing multiple new drug research projects in the fields of metabolic diseases, oncology and autoimmune diseases.
CommBio Therapeutics Co., Ltd 沪ICP备2021004953号-1